A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Have Inadequate Response, Loss of Response, or Intolerance With at Least One of the Following Agents: Immunosuppressant Treatment (i.e. Azathioprine, 6-mercaptopurine, Methotrexate), Tumor Necrosis Factor Alpha [TNF-α] Inhibitors, Vedolizumab, JAK Inhibitors and/or Corticosteroid Treatment
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2019
At a glance
- Drugs ABX 464 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Abivax
- 08 Jan 2019 Planned initiation date changed from 20 Dec 2018 to 20 Jan 2019.
- 29 Nov 2018 Status changed from planning to not yet recruiting.
- 15 Sep 2018 New trial record